Although switching fields has been a challenge, it has also been rewarding. I have learned new ways of thinking about problems in biology that complement the ways I learned as a graduate student. It has also emboldened me for future ventures into new territory.
The Raff experience. I originally trained as a clinical neurologist in Boston and came to London to work with Avrion Mitchison on immunology at the National Institute for Medical Research in Mill Hill. I had not done research before, so I had an intimidating amount to learn. A medical training, I discovered, is not optimal for doing science. In medicine you mainly look backward, comparing what you are seeing now with what others have seen and done before; in science, you struggle to think originally, which is rarely an effective way to treat a patient.
Switching to a new field can invigorate and broaden a scientist
When Mitchison moved to University College London in 1971, I moved with him, to set up a developmental neurobiology group. As an immunologist, I had used antibodies to cell-surface antigens to identify and manipulate different classes of lymphocytes, and I planned to use the same strategy to study neural cells. Remarkably, the Medical Research Council (MRC) awarded us a five-year Programme Grant to do it, even though neither of us had done any neurobiology before.
Kay Fields, a phage molecular biologist, joined the project. She used neural tumour cell lines to raise antibodies that would distinguish different types of normal neural cells, but the strategy mostly failed. It was years before she had an antiserum that specifically recognized Schwann cells in peripheral nerve cultures and allowed us to do our first neurobiology experiments.
These were difficult years. I knew little neurobiology and found it hard to learn more. I remained immersed in immunology, and it was a struggle to switch my interest. My scientific friends were immunologists, I was invited to talk only at immunology meetings, and the young scientists who applied to work with me wanted to do immunology. It was five years before we published our first neurobiology paper, and even longer before I managed to withdraw from immunology completely to become a full-time developmental neurobiologist. I am not sure that I could have made the transition if Jeremy Brockes had not joined the lab as a postdoc. Coming from the Neurobiology Department at Harvard Medical School, then the Mecca of neurobiology, he played a crucial part in my conversion. It was wonderful of the MRC to continue to support us through those lean years, and I wonder if it, or any other funding agency, would do the same today. The antibody strategy eventually paid off in developmental neurobiology, as in so many other areas, especially after the monoclonal antibody revolution.
These days, field-switching usually occurs by chance: you knock out a gene and part of the brain fails to develop; to follow up such findings you have to become a developmental neurobiologist. In this type of situation, switching is relatively painless, as you start with an interesting finding. Whether chosen deliberately or triggered by a chance observation, field switching can bring rich rewards, both to the scientists who do it and to the fields they enter. Perhaps mentors and funding agencies should encourage it more than they do.
